Management of hypertension in patients with left ventricular hypertrophy

被引：15

作者：

Cuspidi, Cesare ^{[1
]}

Sala, Carla ^{[1
]}

Zanchetti, Alberto ^{[1
]}

机构：

[1] Policlin Monza, I-20052 Monza, Italy

来源：

CURRENT HYPERTENSION REPORTS | 2007年 / 9卷 / 06期

关键词：

D O I：

10.1007/s11906-007-0091-6

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Left ventricular hypertrophy (LVH) is a cardinal manifestation of organ damage in patients with arterial hypertension. Identifying LVH is a fundamental step in evaluating hypertensive patients, because clinical and epidemiologic studies have shown this condition has a strong independent adverse prognostic significance. LVH is an integrated marker of cardiovascular risk, reflecting hypertension's hemodynamic and nonhemodynamic effects on the heart. Reversing LVH is an intermediate goal of antihypertensive therapy. Pharmacologic strategies to reverse LVH should be based on combining two or more drugs: a renin-angiotensin system blocker (ie, angiotensin-converting enzyme inhibitor or angiotensin receptor antagonist), and a calcium antagonist or low-dose diuretic. Successful therapeutic plans should also include nonpharmacologic interventions to promote LVH regression.

引用

收藏

页码：498 / 505

页数：8

相关论文

共 49 条

[1] Cardiac structural and functional changes during long-term anti hypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA) [J].

Agabiti-Rosei, E ;

Trimarco, B ;

Muiesan, ML ;

Reid, J ;

Salvetti, A ;

Tang, R ;

Hennig, M ;

Baurecht, H ;

Parati, G ;

Mancia, G ;

Zanchetti, A .

JOURNAL OF HYPERTENSION, 2005, 23 (05) :1091-1098

[2] Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment:: the LIFE study [J].

Bella, JN ;

Palmieri, V ;

Wachtell, K ;

Liu, JE ;

Gerdts, E ;

Nieminen, MS ;

Koren, MJ ;

Zabalgoitia, M ;

Wright, JT ;

Dahlöf, B ;

Devereux, RB .

JOURNAL OF HUMAN HYPERTENSION, 2004, 18 (06) :411-416

[3] LEFT-VENTRICULAR MASS AND RISK OF STROKE IN AN ELDERLY COHORT - THE FRAMINGHAM HEART-STUDY [J].

BIKKINA, M ;

LEVY, D ;

EVANS, JC ;

LARSON, MG ;

BENJAMIN, EJ ;

WOLF, PA ;

CASTELLI, WP .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (01) :33-36

[4] Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease [J].

Brilla, CG ;

Funck, RC ;

Rupp, H .

CIRCULATION, 2000, 102 (12) :1388-1393

[5] TEMPORAL DIFFERENCES IN FIBROBLAST PROLIFERATION AND PHENOTYPE EXPRESSION IN RESPONSE TO CHRONIC ADMINISTRATION OF ANGIOTENSIN-II OR ALDOSTERONE [J].

CAMPBELL, SE ;

JANICKI, JS ;

WEBER, KT .

JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1995, 27 (08) :1545-1560

[6] Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].

Chobanian, AV ;

Bakris, GL ;

Black, HR ;

Cushman, WC ;

Green, LA ;

Izzo, JL ;

Jones, DW ;

Materson, BJ ;

Oparil, S ;

Wright, JT ;

Roccella, EJ .

HYPERTENSION, 2003, 42 (06) :1206-1252

[7] Prognostic value of left ventricular mass and its evolution during treatment in the Bordeaux cohort of hypertensive patients [J].

Cipriano, C ;

Gosse, P ;

Bemurat, L ;

Mas, D ;

Lemetayer, P ;

N'Tela, G ;

Clementy, J .

AMERICAN JOURNAL OF HYPERTENSION, 2001, 14 (06) :524-529

[8] Echocardiographic patterns of myocardial fibrosis in hypertensive patients: Endomyocardial biopsy versus ultrasonic tissue characterization [J].

Ciulla, M ;

Paliotti, R ;

Hess, DB ;

Tjahja, E ;

Campbell, SE ;

Magrini, F ;

Weber, KT .

JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY, 1997, 10 (06) :657-664

[9] Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis -: Results of a randomized trial [J].

Ciulla, MM ;

Paliotti, R ;

Esposito, A ;

Diez, J ;

López, BA ;

Dahlóf, B ;

Nicholls, G ;

Smith, RD ;

Gilles, L ;

Magrini, F ;

Zanchetti, A .

CIRCULATION, 2004, 110 (05) :552-557

[10] Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study [J].

Cuspidi, C ;

Muiesan, ML ;

Valagussa, L ;

Salvetti, M ;

Di Biagio, C ;

Agabiti-Rosei, E ;

Magnani, B ;

Zanchetti, A .

JOURNAL OF HYPERTENSION, 2002, 20 (11) :2293-2300

← 1 2 3 4 5 →